PARP1 and cancer: At the same time, Chen group reported the design and synthesis of PARP1 degraders based on Olaparib and thalidomide/lenalidomide.396 The representative degrader 208 (SK-575, Fig. 61) potently inhibited the growth of cancer cells bearing BRCA1/2 mutations, and induced potent and specific degradation of PARP1 in various human PARP1-positive cancer cells with the Dmax more than 95%.